- Advertisement -
On Monday, the company announced a pathological complete response – no detectable signs of cancer – in a patient enrolled in its ACCENT trial of a drug therapy to limit tumour growth.The trial combined the therapy narmafotinib with two other drugs to treat a patient with metastatic (stage IV)…
Click here to view the original article.
